166 related articles for article (PubMed ID: 37380943)
1. PATH-SURVEYOR: pathway level survival enquiry for immuno-oncology and drug repurposing.
Obermayer AN; Chang D; Nobles G; Teng M; Tan AC; Wang X; Chen YA; Eschrich S; Rodriguez PC; Grass GD; Meshinchi S; Tarhini A; Chen DT; Shaw TI
BMC Bioinformatics; 2023 Jun; 24(1):266. PubMed ID: 37380943
[TBL] [Abstract][Full Text] [Related]
2. DRPPM-PATH-SURVEIOR: Plug-and-Play Survival Analysis of Pathway-level Signatures and Immune Components.
Obermayer A; Chang D; Nobles G; Teng M; Tan AC; Wang X; Eschrich S; Rodriguez P; Grass GD; Meshinchi S; Tarhini A; Chen DT; Shaw T
Res Sq; 2023 Mar; ():. PubMed ID: 36993526
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric
Pollard JA; Guest E; Alonzo TA; Gerbing RB; Loken MR; Brodersen LE; Kolb EA; Aplenc R; Meshinchi S; Raimondi SC; Hirsch B; Gamis AS
J Clin Oncol; 2021 Oct; 39(28):3149-3160. PubMed ID: 34048275
[TBL] [Abstract][Full Text] [Related]
5. Identification of survival-related alternative splicing signatures in acute myeloid leukemia.
Zhang B; Yang L; Wang X; Fu D
Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34212178
[TBL] [Abstract][Full Text] [Related]
6. Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.
Rao AV; Valk PJ; Metzeler KH; Acharya CR; Tuchman SA; Stevenson MM; Rizzieri DA; Delwel R; Buske C; Bohlander SK; Potti A; Löwenberg B
J Clin Oncol; 2009 Nov; 27(33):5580-6. PubMed ID: 19858393
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.
Juul-Dam KL; Shukla NN; Cooper TM; Cuglievan B; Heidenreich O; Kolb EA; Rasouli M; Hasle H; Zwaan CM
Eur J Med Genet; 2023 Dec; 66(12):104869. PubMed ID: 38174649
[TBL] [Abstract][Full Text] [Related]
8. HCK is a Potential Prognostic Biomarker that Correlates with Immune Cell Infiltration in Acute Myeloid Leukemia.
Cheng F; Li Q; Wang J; Wang L; Li W; Zeng F
Dis Markers; 2022; 2022():3199589. PubMed ID: 35280440
[TBL] [Abstract][Full Text] [Related]
9. An Immune Risk Score Predicts Survival of Patients with Acute Myeloid Leukemia Receiving Chemotherapy.
Wang Y; Cai YY; Herold T; Nie RC; Zhang Y; Gale RP; Metzeler KH; Zeng Y; Wang SQ; Pan XY; Yang TH; Wu YB; Zhang Q; Wuxiao ZJ; Du X; Liang ZW; Su YZ; Xu JB; Wang YQ; Liu ZL; Wu JW; Zhang X; Wu BY; Xiao RZ; Wang SB; Li JY; Chi PD; Zhang QY; Chen SL; Qin ZY; Zhang XM; Zhong N; Hiddemann W; Liu QF; Zhang B; Liang Y
Clin Cancer Res; 2021 Jan; 27(1):255-266. PubMed ID: 33262139
[TBL] [Abstract][Full Text] [Related]
10. Survival prediction in acute myeloid leukemia using gene expression profiling.
Lai B; Lai Y; Zhang Y; Zhou M; OuYang G
BMC Med Inform Decis Mak; 2022 Mar; 22(1):57. PubMed ID: 35241089
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a promising 5-gene prognostic model for pediatric acute myeloid leukemia.
Tao Y; Wei L; Shiba N; Tomizawa D; Hayashi Y; Ogawa S; Chen L; You H
Mol Biomed; 2024 Jan; 5(1):1. PubMed ID: 38163849
[TBL] [Abstract][Full Text] [Related]
12. Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23/KMT2A rearrangements.
Yuen KY; Liu Y; Zhou YZ; Wang Y; Zhou DH; Fang JP; Xu LH
Cancer Med; 2023 Jan; 12(2):1418-1430. PubMed ID: 35833755
[TBL] [Abstract][Full Text] [Related]
13. Therapy-induced Deletion in 11q23 Leading to Fusion of
Panagopoulos I; Andersen K; Eilert-Olsen M; Zeller B; Munthe-Kaas MC; Buechner J; Osnes LTN; Micci F; Heim S
Cancer Genomics Proteomics; 2021; 18(1):67-81. PubMed ID: 33419897
[TBL] [Abstract][Full Text] [Related]
14. CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group.
Lamble AJ; Eidenschink Brodersen L; Alonzo TA; Wang J; Pardo L; Sung L; Cooper TM; Kolb EA; Aplenc R; Tasian SK; Loken MR; Meshinchi S
J Clin Oncol; 2022 Jan; 40(3):252-261. PubMed ID: 34855461
[TBL] [Abstract][Full Text] [Related]
15. The Application of Targeted RNA Sequencing for KMT2A-Partial Tandem Duplication Identification and Integrated Analysis of Molecular Characterization in Acute Myeloid Leukemia.
Dai B; Yu H; Ma T; Lei Y; Wang J; Zhang Y; Lu J; Yan H; Jiang L; Chen B
J Mol Diagn; 2021 Nov; 23(11):1478-1490. PubMed ID: 34384895
[TBL] [Abstract][Full Text] [Related]
16. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
Front Immunol; 2022; 13():955063. PubMed ID: 36248850
[TBL] [Abstract][Full Text] [Related]
17. Exploring Prognostic Biomarkers of Acute Myeloid Leukemia to Determine Its Most Effective Drugs from the FDA-Approved List through Molecular Docking and Dynamic Simulation.
Alom MM; Faruqe MO; Molla MKI; Rahman MM
Biomed Res Int; 2023; 2023():1946703. PubMed ID: 37359050
[TBL] [Abstract][Full Text] [Related]
18. SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.
Di Mambro A; Arroyo-Berdugo Y; Fioretti T; Randles M; Cozzuto L; Rajeeve V; Cevenini A; Austin MJ; Esposito G; Ponomarenko J; Lucas CM; Cutillas P; Gribben J; Williams O; Calle Y; Patel B; Esposito MT
Oncogene; 2023 Dec; 42(50):3670-3683. PubMed ID: 37891368
[TBL] [Abstract][Full Text] [Related]
19. A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis.
Morris VS; Ghazi H; Fletcher DM; Guinn BA
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298623
[TBL] [Abstract][Full Text] [Related]
20. Bipartite network analysis reveals metabolic gene expression profiles that are highly associated with the clinical outcomes of acute myeloid leukemia.
Xie F; He M; He L; Liu K; Li M; Hu G; Wen Z
Comput Biol Chem; 2017 Apr; 67():150-157. PubMed ID: 28110245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
